Aarti Drugs Limited (BOM:524348)
374.05
-1.15 (-0.31%)
At close: Jan 21, 2026
Aarti Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 24,767 | 23,870 | 25,286 | 27,161 | 24,886 | 21,548 | Upgrade |
Other Revenue | - | - | - | - | 0 | - | Upgrade |
| 24,767 | 23,870 | 25,286 | 27,161 | 24,886 | 21,548 | Upgrade | |
Revenue Growth (YoY) | 4.08% | -5.60% | -6.90% | 9.14% | 15.49% | 19.31% | Upgrade |
Cost of Revenue | 15,913 | 15,614 | 16,970 | 19,102 | 17,022 | 13,319 | Upgrade |
Gross Profit | 8,854 | 8,256 | 8,316 | 8,058 | 7,865 | 8,229 | Upgrade |
Selling, General & Admin | 1,250 | 1,141 | 1,047 | 933.07 | 840.53 | 815.37 | Upgrade |
Other Operating Expenses | 4,492 | 4,244 | 4,104 | 4,069 | 3,640 | 3,034 | Upgrade |
Operating Expenses | 6,338 | 5,943 | 5,666 | 5,505 | 4,981 | 4,348 | Upgrade |
Operating Income | 2,516 | 2,313 | 2,650 | 2,553 | 2,884 | 3,881 | Upgrade |
Interest Expense | -344.93 | -358.73 | -335.15 | -332.93 | -207.48 | -229.57 | Upgrade |
Interest & Investment Income | 124.09 | 124.09 | 24.97 | 7.02 | 23.16 | 36.2 | Upgrade |
Other Non Operating Income (Expenses) | 39.61 | 39.51 | 15.33 | 14.92 | 0 | -0 | Upgrade |
EBT Excluding Unusual Items | 2,334 | 2,118 | 2,355 | 2,242 | 2,700 | 3,688 | Upgrade |
Asset Writedown | - | - | - | - | - | -30.42 | Upgrade |
Other Unusual Items | - | - | - | - | - | 32.67 | Upgrade |
Pretax Income | 2,334 | 2,118 | 2,355 | 2,242 | 2,700 | 3,690 | Upgrade |
Income Tax Expense | 344.44 | 436.74 | 639.37 | 578.25 | 649.59 | 886.16 | Upgrade |
Earnings From Continuing Operations | 1,990 | 1,681 | 1,716 | 1,664 | 2,050 | 2,804 | Upgrade |
Minority Interest in Earnings | 1.02 | 0.62 | -1.73 | -0.48 | 0.43 | 0.15 | Upgrade |
Net Income | 1,991 | 1,682 | 1,714 | 1,663 | 2,050 | 2,804 | Upgrade |
Net Income to Common | 1,991 | 1,682 | 1,714 | 1,663 | 2,050 | 2,804 | Upgrade |
Net Income Growth | 30.79% | -1.90% | 3.07% | -18.89% | -26.88% | 98.31% | Upgrade |
Shares Outstanding (Basic) | 87 | 91 | 92 | 93 | 93 | 93 | Upgrade |
Shares Outstanding (Diluted) | 87 | 91 | 92 | 93 | 93 | 93 | Upgrade |
Shares Change (YoY) | -5.05% | -0.72% | -0.72% | - | -0.64% | - | Upgrade |
EPS (Basic) | 22.89 | 18.42 | 18.65 | 17.96 | 22.14 | 30.09 | Upgrade |
EPS (Diluted) | 22.89 | 18.42 | 18.65 | 17.96 | 22.14 | 30.09 | Upgrade |
EPS Growth | 37.74% | -1.19% | 3.82% | -18.89% | -26.41% | 98.31% | Upgrade |
Free Cash Flow | 470.62 | 674.22 | 1,326 | -314.97 | -815.61 | 667.19 | Upgrade |
Free Cash Flow Per Share | 5.41 | 7.39 | 14.42 | -3.40 | -8.81 | 7.16 | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 2.500 | Upgrade |
Dividend Growth | - | - | - | - | -60.00% | 400.00% | Upgrade |
Gross Margin | 35.75% | 34.59% | 32.89% | 29.67% | 31.60% | 38.19% | Upgrade |
Operating Margin | 10.16% | 9.69% | 10.48% | 9.40% | 11.59% | 18.01% | Upgrade |
Profit Margin | 8.04% | 7.04% | 6.78% | 6.12% | 8.24% | 13.01% | Upgrade |
Free Cash Flow Margin | 1.90% | 2.83% | 5.24% | -1.16% | -3.28% | 3.10% | Upgrade |
EBITDA | 3,085 | 2,843 | 3,140 | 3,028 | 3,353 | 4,335 | Upgrade |
EBITDA Margin | 12.46% | 11.91% | 12.42% | 11.15% | 13.47% | 20.12% | Upgrade |
D&A For EBITDA | 569.34 | 530.44 | 489.77 | 475.43 | 469.4 | 453.3 | Upgrade |
EBIT | 2,516 | 2,313 | 2,650 | 2,553 | 2,884 | 3,881 | Upgrade |
EBIT Margin | 10.16% | 9.69% | 10.48% | 9.40% | 11.59% | 18.01% | Upgrade |
Effective Tax Rate | 14.75% | 20.62% | 27.15% | 25.79% | 24.06% | 24.01% | Upgrade |
Revenue as Reported | 24,908 | 24,034 | 25,326 | 27,182 | 25,000 | 21,593 | Upgrade |
Advertising Expenses | - | 17.91 | 23.3 | 11.67 | 13.5 | 9.81 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.